Mixed reactions to St. Jude's latest Fame II stent study

August 28, 2012 by MassDevice staff

More findings and analysis from St. Jude Medical's Fame II trial, studying fractional flow reserve-directing coronary stenting, leave some with "more questions than answers."

St. Jude Medical's Fame II FFR study

St. Jude Medical (NYSE:STJ) again touted results from its Fame II stenting study, reporting that patients who received percutaneous coronary intervention in addition to drug therapy were better off than patients who took drugs alone, but not all voices in the crowd were ready to accept the results.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.